By Greg Roumeliotis and Ben Martin
LONDON (Reuters) - Takeda Pharmaceutical has made an indicative takeover proposal to British drugmaker Shire worth about 46.50 pounds a share, according to two sources with direct knowledge of the matter.
That would value London-listed Shire at about 43 billion pounds ($61 billion), according to Reuters data.
The move comes ahead of a deadline for the Japanese group to make a firm offer or walk away from the FTSE 100 company by April 25. Shares in Shire were up 5.3 percent at 39.59 pounds at 1032 GMT.
Takeda confirmed last month it was considering an offer for Shire, a rare disease specialist.
A spokesman for Takeda declined to comment and Shire did not return a request for comment.
($1 = 0.7039 pounds)
(Reporting by Greg Roumeliotis and Ben Martin; Editing by Jason Neely and Mark Potter)
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
